However, plasmin-mediated hyperfibrinolysis may also be corrected by all-trans retinoic acid (ATRA) or ATRA plus arsenic trioxide therapy in patients with APL [70] by downregulating ANXA2 expression [71]. Here, ANXA2 is linked to acute promyelocytic leukemia.